UCL Cancer Institute, Paul O’Gorman Building, London

30 March 2005
UCL Cancer Institute, Paul O’Gorman Building, London
Opened in 2007
The new Cancer Institute co-ordinates all of the cancer research taking place within University College London.

We contributed £2 million towards the cost of this important new facility. In recognition of our contribution, the building in which the Institute is housed has been named the Paul O'Gorman Building.
The Institute houses over 350 scientists and clinicians, embedded within one of the finest, largest and most productive biomedical faculties in Europe. It provides a focus for excellent basic science and translational studies across the College’s different sites.

Included within the Institute are substantial new facilities for research into cancers of childhood and adolescence.

We have subsequently provided project funding to support important work taking place in the Institute.

A £1 million project grant in 2007 helped to take forward three different areas of work, all of which have now delivered important progress in the fight against childhood cancer, including steps toward the development of a new drug that could be effective against a number of different cancers.

In 2010 we awarded funding of £330,000 to Professor Tariq Enver, now the Director of the Institute, to underpin his ground-breaking work on leukaemic stem cells.
Read more: The biology of normal and leukaemic stem and progenitor cells

In 2012 Professor Enver was awarded further funding out of our joint funding call with Great Ormond Street Hospital Children’s Charity. A combined grant of £285,000 is supporting a project looking at the role of the leukaemic stem cell in disease relapse.
Read more: The role of the leukaemic stem cell in disease relapse

In 2013 a grant of £243,599 was awarded to a team led by Dr Ariadna Mendoza for a project that builds on progress made under the initial £1 million grant and takes forward the development of a new treatment approach for young patients with Ewing sarcoma, a form of bone cancer.
Read more: A novel combination therapy to treat metastatic Ewing sarcoma

Back to research facilities


Where your money goes

Hover over a segment for details